Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Drug Interaction (DDI) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

NCT06547554
View directory record Official record
Conditions
Bacterial Infections
Interventions
Xeruborbactam, Cefiderocol, Xeruborbactam/Cefiderocol, Dextrose 5% in water
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

NCT02520752
View directory record Official record
Conditions
cMET-dysregulated Advanced Solid Tumors
Interventions
INC280, Midazolam, Caffeine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

NCT02277600
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Darunavir, Cobicistat
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Jun 11, 2026, 5:57 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)

NCT07335419
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
PF-07248144, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction (DDI) Study for TD-9855

NCT03432793
View directory record Official record
Conditions
Drug Drug Interaction (DDI)
Interventions
TD-9855, Fluvoxamine, Itraconazole, Caffeine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

NCT07160738
View directory record Official record
Conditions
Healthy Adults
Interventions
PF-07220060, Itraconazole, Probenecid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 11, 2026, 5:57 AM EDT
Recruiting Phase 1 Interventional

Drug-Drug Interaction Study of ABP-671 in Gout Patients

NCT07367971
View directory record Official record
Conditions
Gout Chronic, Gout, DDI (Drug-Drug Interaction)
Interventions
ABP-671 plus allopurinol
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 11, 2026, 5:57 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

NCT06733675
View directory record Official record
Conditions
Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
Interventions
Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

NCT02480894
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

NCT04008186
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

NCT00000971
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Zidovudine, Didanosine
Drug
Lead sponsor
Abbott
Industry
Eligibility
3 Months to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2008 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants

NCT06370728
View directory record Official record
Conditions
Healthy
Interventions
Orforglipron, Carbamazepine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DDI Effectiveness and Clinical Awareness

NCT03581994
View directory record Official record
Conditions
Drug-Drug Interactions
Interventions
DDI Test Report
Diagnostic Test
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants

NCT04134715
View directory record Official record
Conditions
Healthy
Interventions
PF-06826647, Oral Contraceptive (OC)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

NCT06194214
View directory record Official record
Conditions
Healthy
Interventions
Pirtobrutinib, Digoxin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jun 11, 2026, 5:57 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

NCT07629999
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, Rosuvastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia

NCT06056570
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
dotinurad, dotinurad + allopurinol, allopurinol
Drug
Lead sponsor
Urica Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Clearwater, Florida • Miami Lakes, Florida • Mesquite, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals

NCT00000772
View directory record Official record
Conditions
HIV Infections
Interventions
Ribavirin, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
2
States / cities
Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

NCT00860275
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BMS-708163, BMS-708163 + Ketoconazole, Ketoconazole, Fluconazole, BMS-708163 + Fluconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

NCT02311946
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Alone, Palbociclib + Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Miami, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction (DDI) Rifabutin

NCT02138084
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Rifabutin, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jun 11, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Results available

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

NCT04537715
View directory record Official record
Conditions
All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
Interventions
Tazemetostat, Itraconazole, Rifampin
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Encinitas, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jun 11, 2026, 5:57 AM EDT